# A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

> **NCT04083235** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 770 (actual)

## Conditions studied

- Metastatic Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** Irinotecan Liposomal Injection
- **DRUG:** Oxaliplatin
- **DRUG:** 5Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04083235
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2022-07-23
- **Final completion:** 2025-02-18
- **Target enrollment:** 770 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04083235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04083235, "A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04083235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*